Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Background KRAS G12C mutations are present in around 4% of patients with colorectal cancer and are associated with lower treatment response rates and overall survival. EGFR signalling has been identified as a primary mechanism of resistance to KRAS G12C inhibitors. We aimed to evaluate the efficacy and safety of a novel, covalent, small molecule KRAS G12C inhibitor, glecirasib (JAB-21822), as monotherapy or in combination with the anti-EGFR cetuximab, in patients with KRAS G12C-mutated colorectal cancer.Methods JAB-21822-1002 was an open-label, non-randomised, dose escalation (phase 1) and expansion (phase 2a) trial evaluating glecirasib monotherapy in KRAS G12C-mutated solid tumours. JAB-21822-1007 was an open-label, non-randomised, dose escalation (phase 1b) and expansion (phase 2) study evaluating glecirasib plus cetuximab in KRAS G12C-mutated colorectal, small intestine, and appendiceal cancer. Adult participants (aged ≥18 years) were recruited in China from 17 hospitals for the monotherapy trial and 16 hospitals for the combination trial. Here, we report only on patients with colorectal cancer treated with oral glecirasib at the recommended phase 2 dose (800 mg once daily in 21-day treatment cycles [until disease progression, intolerable toxicity, investigator's discretion, or withdrawal of consent]), pooling phase 1 and 2 data together. In the combination trial, cetuximab was administered intravenously with an initial loading dose of 400 mg/m 2 in the first week, followed by 250 mg/m 2 every week or 500 mg/m 2 every 2 weeks. For this analysis, key eligibility criteria were histologically or cytologically confirmed locally advanced or metastatic colorectal cancer with KRAS G12C mutation; Eastern Cooperative Oncology Group performance status of 0 or 1; and at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST). For phase 1 of both trials, patients must not have responded to, were not suitable for, or refused standard of care. For phase 2 of both trials, patients must have received at least first-line standard of care and had disease progression or intolerance. Primary endpoints for the monotherapy trial were safety (treatment-emergent adverse events, serious adverse events, treatment-related adverse events, dose-limiting toxicity, and clinically significant changes in vital signs, physical examination, and electrocardiography, and clinically significant unexpected laboratory values of grade ≥3) for phase 1 and objective response rate (complete and partial response) for phase 2a. Primary endpoints for the combination trial were dose-limiting toxicities, maximum tolerated dose, and recommended phase 2 dose for phase 1b and objective response rate for phase 2. The full analysis set was defined as patients with at least one measurable lesion at baseline who received at least one dose of glecirasib in the monotherapy trial, or at least one dose of glecirasib plus cetuximab in the combination trial. The safety analysis set was defined as patients who received at least one dose of glecirasib in the monotherapy trial, or at least one dose of glecirasib or cetuximab in the combination trial. The trials are registered with ClinicalTrials.gov (NCT05009329 and NCT05194995), and are active but no longer recruiting.Findings Between Oct 12, 2021, and Dec 4, 2023, 44 patients with colorectal cancer (27 male and 17 female) in the monotherapy trial received glecirasib 800 mg once daily and comprised the full analysis and safety analysis sets. Between Feb 17, 2022, and Feb 28, 2023, 47 patients with colorectal cancer (22 male and 25 female) in the combination trial received glecirasib 800 mg once daily plus cetuximab and comprised the safety analysis set. One patient was excluded from the full analysis set as they received glecirasib only. Data cutoff was June 30, 2024. Median follow-up was 21·9 months (IQR 20·0-25·5) in the monotherapy trial and 18·7 months (15·9-20·6) in the combination trial. In the monotherapy trial phase 1, 15 patients with colorectal cancer were enrolled. No dose-limiting toxicities, unexpected grade 3 or worse laboratory values, or changes in vital signs, physical examinations, or electrocardiography were observed. 15 (100%) patients had treatment-emergent adverse events (n=8 [53%] grade ≥3), 13 (87%) of 15 reported treatment-related adverse events (n=4 (27%) grade ≥3); five (33%) of 15 patients had serious treatment-emergent adverse events, none were treatment-related. In the combination trial phase 1b, six patients with colorectal cancer were enrolled. No dose-limiting toxicities were observed and the maximum tolerated dose was not reached. The recommended phase 2 dose was chosen as glecirasib 800 mg once daily. Objective response rate was 23% (95% CI 11-38; ten of 44 patients [ten partial responses]) in the monotherapy trial and 50% (35-65; 23 of 46 patients [23 partial responses]) in the combination trial. The most common treatment-related adverse events were anaemia (24 [55%]), blood bilirubin increased (23 [52%]), and conjugated bilirubin increased (17 [39%]) in the monotherapy trial, and rash (39 [83%]), blood bilirubin increased (29 [62%]), conjugated bilirubin increased (17 [36%]), alanine aminotransferase increased (16 [34%]), and anaemia (15 [32%]) in the combination trial. The incidence of grade 3 or 4 treatment-related adverse events was 20% (nine of 44) in the monotherapy trial and 19% (nine of 47) in the combination trial. Two (5%) of 44 patients in the monotherapy trial (febrile neutropenia, n=2) and four (9%) of 47 patients in the combination trial (interstitial lung disease [n=1], pleural effusion and pericardial effusion [n=1], pyrexia [n=1], and rash [n=1]) reported serious treatment-related adverse events. No treatment-related deaths were observed in either trial.Interpretation Glecirasib monotherapy and its combination with cetuximab represent potential treatment options for patients with advanced, refractory colorectal cancer harbouring KRAS G12C mutations. The promising efficacy and safety support further exploration of glecirasib-based combinations in earlier lines of treatment.Funding Jacobio.Translation For the Mandarin translation of the abstract see Supplementary Materials section.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Li, J., Qin, S., Xu, R., Yau, T. C. C., Ma, B., Pan, H., Xu, J., Bai, Y., Chi, Y., Wang, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70156-7 · Cited by 813
Self-citationAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467
Li, J., Qin, S., Xu, R.-H., Shen, L., Xu, J., Bai, Y., Yang, L., Deng, Y., Chen, Z.-D., Zhong, H., et al. (2018) · JAMA · doi:10.1001/jama.2018.7855 · Cited by 425
Self-citation
Research works printed but not linked: 4
- Bray, 2024, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 74, 229
- Henry, 2021, Comprehensive clinical and molecular characterization of KRASG12C-mutant colorectal cancer, JCO Precis Oncol, 5
- Schirripa, 2020, KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population, Clin Colorectal Cancer, 19, 219
- Li, 2022, A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors, Proc Am Soc Clin Oncol, 40
Cited by
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Jiang, L., Luo, Y., Liang, H., Feng, X., Huang, Y., Li, Y., Wang, Z., Xu, T., Zou, H., Li, Z., et al. (2026) · Human Cell · doi:10.1007/s13577-026-01405-0
Self-citationYang, X., Tao, X., Qi, W., Luo, R., Lan, T., Xie, K., Cai, Y., Gao, F., Lv, Y., Liu, C., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101718
KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
Cai, J., Wu, Y., Jia, X., Yang, L., Yang, W., Lu, W., Huang, Z., Pan, Y., Fei, Z., Ru, J., et al. (2026) · MedComm · doi:10.1002/mco2.71050 · Cited by 1
Metadata
- Authors
- Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., Zhu, L., An, G., Zhang, Y., Li, Z., Li, Y., Gu, Y., Hu, C., Li, X., Huang, C., Fu, Q., Yin, X., Liang, X., Zhong, D., Shi, H., Li, X., Li, Z., Liu, L., Wang, F., Liang, R., Xia, G., Wang, Z., Wang-Gillam, A., Ding, Y., Rao, Z., Pan, W., Lu, S., Sun, X., & Shen, L.
- Affiliations
- Peking University Cancer Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Peking University Third Hospital (CN)
- Zhengzhou University (CN)
- Fudan University (CN)
- Peking Union Medical College Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Jiangsu Cancer Hospital (CN)
- Capital Medical University (CN)
- Harbin Medical University (CN)
- Chongqing University (CN)
- Jiangsu Province Hospital (CN)
- Central South University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Hubei Cancer Hospital (CN)
- Tianjin Medical University General Hospital (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Shandong University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Guangxi Medical University (CN)
- Corresponding author
- Shen, Lin
- ORCID
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2026-02
- Volume
- 11
- Issue
- 2
- Pages
- 110-123
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W4416889006
- Cited by
- 3
- References
- 42
- Citations by year
- 2026: 3
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS G12C mutation, colorectal cancer, cetuximab, EGFR inhibition, KRAS G12C inhibitors, metastatic colorectal cancer, locally advanced colorectal cancer, combination therapy, dose escalation, treatment efficacy and safety, anti-EGFR resistance, small intestine neoplasms, appendiceal neoplasms
- MeSH terms
- Cetuximab, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials. https://app.cochat.ai/papers/10.1016/s2468-1253(25)00267-5
- The paper
- Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., Zhu, L., An, G., Zhang, Y., Li, Z., Li, Y., Gu, Y., Hu, C., Li, X., Huang, C., . . . Shen, L. (2026). Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(25)00267-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.